Cipla Limited
CIPLA
Clasificación en acciones
#1804
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Precio por acción
$14.64
Capitalización bursátil
$11.83B
Cambio (1 día)
0.10%
Cambio (1 año)
-18.29%
País
IN
Comercio Cipla Limited (CIPLA)
Categoría
Healthcare
EPS de Cipla Limited (CIPLA)
EPS a fecha de June 2026 TTM: $0.46
Según los últimos informes financieros y el precio de las acciones de Cipla Limited, el EPS actual de la empresa (TTM) es $0.46. Al final del año 2024, la empresa tenía un EPS de $0.61 un aumento con respecto a al EPS de 2023, que fue de $0.42.
Historial de EPS de Cipla Limited desde 2004 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $0.46 | -39.39% |
| 2025 | $0.76 | 24.70% |
| 2024 | $0.61 | 44.90% |
| 2023 | $0.42 | 2.80% |
| 2022 | $0.41 | 0.88% |
| 2021 | $0.41 | 59.95% |
| 2020 | $0.25 | -6.77% |
| 2019 | $0.27 | 1.49% |
| 2018 | $0.27 | 39.41% |
| 2017 | $0.19 | -24.42% |
| 2016 | $0.26 | 8.40% |
| 2015 | $0.24 | -18.30% |
| 2014 | $0.29 | -18.53% |
| 2013 | $0.35 | 26.01% |
| 2012 | $0.28 | 1.66% |
| 2011 | $0.28 | -9.38% |
| 2010 | $0.31 | 56.09% |
| 2009 | $0.20 | -13.31% |
| 2008 | $0.23 | 13.49% |
| 2007 | $0.20 | 9.18% |
| 2006 | $0.18 | 45.52% |
| 2005 | $0.13 | 37.67% |
| 2004 | $0.09 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 20.78% |
IN
|
